Aria Plans Clinical Trial of T21 Dx in 25K Women; Says Test Does Not Infringe Sequenom IP | GenomeWeb

By Monica Heger

This story was originally published Jan. 17.

Aria Diagnostics is planning to launch a clinical trial of its noninvasive sequencing-based trisomy 21 test in 25,000 women.

Aria's CEO Ken Song told Clinical Sequencing News last week that the company plans to launch its test in the US in the first half of this year for under $1,000 with a turnaround time of about one week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.